Estrella Immunopharma (ESLA)

Executive Summary

Estrella Immunopharma is a clinical-stage biotechnology company developing next-generation T-cell immunotherapies based on its proprietary CD19-Redirected ARTEMIS™ platform. The platform is designed to reduce the risk of cytokine release syndrome (CRS) while maintaining potent anti-tumor activity. Estrella is initially targeting CD19-positive hematologic malignancies and is also advancing a novel 'mark-and-kill' approach for solid tumors using oncolytic viruses. As a public company (NASDAQ: ESLA), Estrella is well-positioned to address significant unmet needs in oncology and autoimmune diseases. The company's valuation of approximately $53 million and recent public listing provide a platform for growth, though it remains in early clinical stages with no approved products. Key upcoming milestones include initial clinical data from its lead program in B-cell malignancies and proof-of-concept results for the solid tumor platform.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 interim data from ARTEMIS™ trial in relapsed/refractory B-cell malignancies40% success
• Q2 2027IND filing for solid tumor 'mark-and-kill' program using oncolytic virus60% success
• H1 2027Partnering or licensing deal for ARTEMIS™ platform in autoimmune indications35% success